BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 30179602)

  • 1. Identification of the UBA2-WTIP fusion gene in acute myeloid leukemia.
    Lu X; Zhuang H; Yu Q; Zhang X; Wu Z; Zhang L; Xu Y; Wu B; Yang L; Ma A; Gan X; Yu X; Shen J; Xu R
    Exp Cell Res; 2018 Oct; 371(2):409-416. PubMed ID: 30179602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biologic activity of triptolide in t(8;21) acute myeloid leukemia cells.
    Zhou GS; Hu Z; Fang HT; Zhang FX; Pan XF; Chen XQ; Hu AM; Xu L; Zhou GB
    Leuk Res; 2011 Feb; 35(2):214-8. PubMed ID: 20691473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-dose triptolide enhances antitumor effect of JQ1 on acute myeloid leukemia through inhibiting RNA polymerase II in vitro and in vivo.
    Shi Y; Zhao H; Ye J; Li Z; Deng M; Zha J; Zhou Y; Zeng H; Lin Y; Pu X; Guo C; Song H; Qiu Y; Xu B
    Mol Carcinog; 2020 Sep; 59(9):1076-1087. PubMed ID: 32691884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cryptotanshinone suppresses key onco-proliferative and drug-resistant pathways of chronic myeloid leukemia by targeting STAT5 and STAT3 phosphorylation.
    Dong B; Liang Z; Chen Z; Li B; Zheng L; Yang J; Zhou H; Qu L
    Sci China Life Sci; 2018 Sep; 61(9):999-1009. PubMed ID: 30054832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low HOX gene expression in PML-RARα-positive leukemia results from suppressed histone demethylation.
    Rejlova K; Musilova A; Kramarzova KS; Zaliova M; Fiser K; Alberich-Jorda M; Trka J; Starkova J
    Epigenetics; 2018; 13(1):73-84. PubMed ID: 29224413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional analysis of the two reciprocal fusion genes MLL-NEBL and NEBL-MLL reveal their oncogenic potential.
    Emerenciano M; Kowarz E; Karl K; de Almeida Lopes B; Scholz B; Bracharz S; Meyer C; Pombo-de-Oliveira MS; Marschalek R
    Cancer Lett; 2013 May; 332(1):30-4. PubMed ID: 23340173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low dose triptolide reverses chemoresistance in adult acute lymphoblastic leukemia cells via reactive oxygen species generation and DNA damage response disruption.
    Zhao H; Shi P; Deng M; Jiang Z; Li Y; Kannappan V; Wang W; Li P; Xu B
    Oncotarget; 2016 Dec; 7(51):85515-85528. PubMed ID: 27888802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extracellular matrix stiffness causes systematic variations in proliferation and chemosensitivity in myeloid leukemias.
    Shin JW; Mooney DJ
    Proc Natl Acad Sci U S A; 2016 Oct; 113(43):12126-12131. PubMed ID: 27790998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PML/RARα-Regulated miR-181a/b Cluster Targets the Tumor Suppressor RASSF1A in Acute Promyelocytic Leukemia.
    Bräuer-Hartmann D; Hartmann JU; Wurm AA; Gerloff D; Katzerke C; Verga Falzacappa MV; Pelicci PG; Müller-Tidow C; Tenen DG; Niederwieser D; Behre G
    Cancer Res; 2015 Aug; 75(16):3411-24. PubMed ID: 26041820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. WTIP upregulates FOXO3a and induces apoptosis through PUMA in acute myeloid leukemia.
    Zhu Y; Tong X; Wang Y; Lu X
    Cell Death Dis; 2021 Dec; 13(1):18. PubMed ID: 34930905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
    Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
    Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological targeting of miR-155 via the NEDD8-activating enzyme inhibitor MLN4924 (Pevonedistat) in FLT3-ITD acute myeloid leukemia.
    Khalife J; Radomska HS; Santhanam R; Huang X; Neviani P; Saultz J; Wang H; Wu YZ; Alachkar H; Anghelina M; Dorrance A; Curfman J; Bloomfield CD; Medeiros BC; Perrotti D; Lee LJ; Lee RJ; Caligiuri MA; Pichiorri F; Croce CM; Garzon R; Guzman ML; Mendler JH; Marcucci G
    Leukemia; 2015 Oct; 29(10):1981-92. PubMed ID: 25971362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The PAF complex regulation of Prmt5 facilitates the progression and maintenance of MLL fusion leukemia.
    Serio J; Ropa J; Chen W; Mysliwski M; Saha N; Chen L; Wang J; Miao H; Cierpicki T; Grembecka J; Muntean AG
    Oncogene; 2018 Jan; 37(4):450-460. PubMed ID: 28945229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The t(8;21) fusion protein RUNX1-ETO downregulates PKM2 in acute myeloid leukemia cells.
    Yan JS; Li YD; Liu SH; Yin QQ; Liu XY; Xia L; Lu Y
    Leuk Lymphoma; 2017 Aug; 58(8):1985-1988. PubMed ID: 28092997
    [No Abstract]   [Full Text] [Related]  

  • 15. Triptolide decreases expression of latency-associated nuclear antigen 1 and reduces viral titers in Kaposi's sarcoma-associated and herpesvirus-related primary effusion lymphoma cells.
    Long C; Guo W; Zhou H; Wang J; Wang H; Sun X
    Int J Oncol; 2016 Apr; 48(4):1519-30. PubMed ID: 26821279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PML/RARalpha, a fusion protein in acute promyelocytic leukemia, prevents growth factor withdrawal-induced apoptosis in TF-1 cells.
    Fu S; Consoli U; Hanania EG; Zu Z; Claxton DF; Andreeff M; Deisseroth AB
    Clin Cancer Res; 1995 Jun; 1(6):583-90. PubMed ID: 9816019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergism of cytotoxicity effects of triptolide and artesunate combination treatment in pancreatic cancer cell lines.
    Liu Y; Cui YF
    Asian Pac J Cancer Prev; 2013; 14(9):5243-8. PubMed ID: 24175808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. C-Myc-dependent repression of two oncogenic miRNA clusters contributes to triptolide-induced cell death in hepatocellular carcinoma cells.
    Li SG; Shi QW; Yuan LY; Qin LP; Wang Y; Miao YQ; Chen Z; Ling CQ; Qin WX
    J Exp Clin Cancer Res; 2018 Mar; 37(1):51. PubMed ID: 29523159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FLT3-ITD confers resistance to the PI3K/Akt pathway inhibitors by protecting the mTOR/4EBP1/Mcl-1 pathway through STAT5 activation in acute myeloid leukemia.
    Nogami A; Oshikawa G; Okada K; Fukutake S; Umezawa Y; Nagao T; Kurosu T; Miura O
    Oncotarget; 2015 Apr; 6(11):9189-205. PubMed ID: 25826077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pirin downregulation is a feature of AML and leads to impairment of terminal myeloid differentiation.
    Licciulli S; Cambiaghi V; Scafetta G; Gruszka AM; Alcalay M
    Leukemia; 2010 Feb; 24(2):429-37. PubMed ID: 20010624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.